Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing this week
April 30, 2026 News
Hemab Therapeutics prices upsized IPO at $18, the high end of the range
Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, raised $302 million by offering 16.8 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 11.8 million shares at the same range, before it increased the proposed share offering on Thursday morning. At pricing, Hemab raised just over 50% more in proceeds than originally planned.
April 30, 2026 News
Coagulation disorder biotech Hemab Therapeutics Holdings ups shares offered by 27% ahead of $255 million IPO
Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, raised the proposed deal size for its upcoming IPO on Thursday.
The Cambridge, MA-based company now plans to raise $255 million by offering 15 million shares at a price range of $16 to $18. The company had previously filed to offer 11.8 million shares at the same range. At the midpoint, Hemab Therapeutics Holdings will raise 27% more in proceeds than previously anticipated.
IPO Overview
Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18.
Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig （HMB-001）， finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.
Hemab Therapeutics Holdings was founded in 2020. It plans to list on the Nasdaq under the symbol COAG. Goldman Sachs, Jefferies, and Evercore ISI are the joint bookrunners on the deal. It is expected to price the week of April 27, 2026.
About the Company
We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig （HMB-001）， is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets.